Stock Events

Stock Events

Moderna 

€123.96
3052
-€0.20-0.16% 14:34 Today

Statistics

Day High
124.56
Day Low
123.34
52W High
136.12
52W Low
20.07
Volume
4,916
Avg. Volume
-
Mkt Cap
49.49B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-4.45
-3.13
-1.82
-0.51
Expected EPS
-1.099469
Actual EPS
N/A

Financials

-148.57%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
1.66BRevenue
-2.47BNet Income

Analyst Ratings

69.05Average Price Target
The highest estimate is 136.58.
From 14 ratings within the last 6 months. This is not an investment recommendation.
Buy
21%
Hold
57%
Sell
21%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0QF.XETRA. It's not an investment recommendation.
Apple
737
AAPL
Tesla
686
TSLA
Microsoft
673
MSFT
Amazon
634
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap162.16B
Pfizer is a direct competitor in the COVID-19 vaccine market, with its mRNA vaccine developed in collaboration with BioNTech.
BioNTech
BNTX
Mkt Cap26.06B
BioNTech SE partnered with Pfizer to develop a COVID-19 mRNA vaccine, competing directly with Moderna's mRNA vaccine.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson competes in the COVID-19 vaccine space with its viral vector vaccine, offering an alternative to mRNA vaccines.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca competes with Moderna with its COVID-19 vaccine developed in collaboration with Oxford University, using a different technology (viral vector).
Novavax
NVAX
Mkt Cap1.69B
Novavax offers a protein subunit COVID-19 vaccine, providing an alternative to Moderna's mRNA vaccine.
Sanofi
SNY
Mkt Cap106.01B
Sanofi, through its partnership with GlaxoSmithKline, is developing COVID-19 vaccines that compete with Moderna's offerings.
GSK
GSK
Mkt Cap99.96B
GlaxoSmithKline, in collaboration with Sanofi, is working on COVID-19 vaccines, positioning it as a competitor to Moderna.
Merck
MRK
Mkt Cap370.89B
Merck is involved in the development of COVID-19 treatments and vaccines, making it a competitor in the broader infectious disease market.
Abbott Laboratories
ABT
Mkt Cap187.45B
Abbott Laboratories competes with Moderna in the broader healthcare sector, including diagnostics and medical devices for infectious diseases.

About

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Show more...
CEO
Stéphane Bancel
Employees
4700
Country
United States
ISIN
US60770K1079
WKN
000A2N9D9

Listings

STU
DE
0QF.STU
MU
DE
0QF.MU
LSE
GB
0A45.LSE
SA
BR
M1RN34.SA

0 Comments

Share your thoughts

FAQ

What is Moderna stock price today?▼
The current price of 0QF.XETRA is €123.96 EUR — it has decreased by -0.16% in the past 24 hours. Watch Moderna stock price performance more closely on the chart.
What is Moderna stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XETRA Stock Exchange exchange Moderna stocks are traded under the ticker 0QF.XETRA.
Is Moderna stock price growing?▼
0QF.XETRA stock has risen by +1.22% compared to the previous week, the month change is a +150.2% rise, over the last year Moderna has showed a +484.96% increase.
What is Moderna market cap?▼
Today Moderna has the market capitalization of 49.49B
When is the next Moderna earnings date?▼
Moderna is going to release the next earnings report on October 29, 2026.
What were Moderna earnings last quarter?▼
0QF.XETRA earnings for the last quarter are -1.71 EUR per share, whereas the estimation was -1.76 EUR resulting in a +3.06% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Moderna revenue for the last year?▼
Moderna revenue for the last year amounts to 1.66B EUR.
What is Moderna net income for the last year?▼
0QF.XETRA net income for the last year is -2.47B EUR.
How many employees does Moderna have?▼
As of September 07, 2026, the company has 4,700 employees.
In which sector is Moderna located?▼
Moderna operates in the Health & Wellness sector.
When did Moderna complete a stock split?▼
The last stock split for Moderna was on August 03, 2017 with a ratio of 1:10.
Where is Moderna headquartered?▼
Moderna is headquartered in CAMBRIDGE, United States.